G
Gen1E Lifesciences
Developing immunomodulators for rare and inflammatory diseases
About Gen1E Lifesciences
GEn1E Lifesciences is a biotech company specializing in the development of selective kinase inhibitors aimed at treating inflammatory and age-related diseases. The company operates in the pharmaceutical and biotechnology market, focusing on preclinical and clinical research to bring innovative treatments to patients. Its lead program targets acute respiratory distress syndrome (ARDS), a severe lung condition often seen in critically ill patients, including those with COVID-19. GEn1E's business model involves the commercialization of proprietary compounds developed in collaboration with the University of Maryland, Baltimore. The company generates revenue through licensing agreements and partnerships with other biotech firms and research institutions. GEn1E's CEO, Dr. Ritu Lal, brings over 20 years of experience in pharmaceutical R&D, having successfully taken multiple compounds from discovery to regulatory approval. The company is backed by prominent accelerators like Y Combinator and has strong ties to the Baltimore biotech ecosystem.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Dec 2022 | $17M | $68M | Undisclosed | — |
| SEED✓Equity / VC | Aug 2021 | — | — | 10X Capital | — |
Growth signals
Latest recorded traffic for Gen1E Lifesciences is 290 monthly website visits, up 0% over the last three months. Gen1E Lifesciences's team grew 63.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Gen1E Lifesciences in the Palo Alto ecosystem
The Gen1E Lifesciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Khosla Ventures
Stanford Angels and Entrepreneurs
10X Capital
Other known investors7 additional known investors
University of Maryland Baltimore County
Flucas Ventures
Harmonix
Leblon Capital
StartX
SV Latam Capital
Y Combinator
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Gen1E Lifesciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Gen1E Lifesciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









